Serine protease factor Xa (fXa), positioned at the juncture of the intrinsic and the extrinsic pathways, plays a pivotal role in the blood coagulation cascade.
Serine protease factor Xa (fXa), positioned at the juncture of the intrinsic and the extrinsic pathways, plays a pivotal role in the blood coagulation cascade. 1) Selective inhibition of fXa without affecting the existing thrombin levels may cause less impairment of primary hemostasis and thus should be a safer anticoagulant therapy than direct inhibition of thrombin. Clinical findings have confirmed the potential of fXa inhibition for producing excellent antithrombotic efficacy with minimal bleeding risk when compared to direct thrombin inhibitors. [2] [3] [4] [5] [6] Our previous communications have reported a series of 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as potent and selective fXa inhibitors with good oral bioavailability and half-life. [7] [8] [9] This class of fXa inhibitors, as represented by compounds 1-4, possesses a substituent either at the 6-position (chloro) or at the 3-position (methylsulfonyl, aminosulfonyl, aminocarbonyl, fluoro or cyano) on the P1 naphthalene moiety. The individual fXa affinity enhancing effect of the 6-chloro and the 3-methylsulfonyl substituents prompted us to wonder if the two substituents could be synergetic to each other for further fXa binding potency improvement. To answer this question, we designed compounds 5 and 6 that bear a tri-b-substituted 6-chloro-3-methylsulfonyl naphthalene moiety as the fXa S1 binding element.
Ethyl 1-(6-chloro-3-(methylsulfonyl)naphthalen-2-yl)-3-methyl-1H-pyrazole-5-carboxylate 7 was the key building block needed for the synthesis of compounds 5 and 6, and the tri-b-substituted naphthalene 8 would be the precursor for its preparation, as analyzed in Chart 1. The amino group would lead to the pyrazole via condensation of the corresponding hydrazine, and the iodo group would serve as a handle to install the methylsulfonyl substituent through a copper-mediated C-S cross coupling with sodium methanesulfinate.
10) 6-Chloro-3-iodo-2-naphthylamine 8 could be synthesized from methyl 3-amino-2-naphthoate 9 via iodode-diazoniation followed by Curtius rearrangement. Based upon Levy's precedent work, 11) compounds 9-11 could be prepared from the Diels-Alder product 12 of 4-chloro-oquinodimethane (13) and maleic anhydride. To produce the o-quinodimethane in situ, Levy forced the cheletropic elimination of sulfur dioxide from 1,3-dihydrobenzo[c]thiophene-S,S-dioxide using strong heat at 230°C. In direct contrast, the 1,4-dihydro-2,3-benzoxathiin-3-oxide (also known as sulfinate or sultine) undergoes the sulfur dioxide cheletropic elimination smoothly around 80°C. [12] [13] [14] [15] [16] [17] Hoey and Dittmer 13) have developed a convenient one-step synthesis of 1,4-dihydro-2,3-benzoxathiin-3-oxide in high yield from a,aЈ-dihalo-o-xylene and sodium hydroxymethanesulfinate (rongalite). Townsend and co-workers 12) have elegantly applied this methodology in the preparation of tetra-b-substituted naphthalenes. We thus chose sulfinate 15 over sulfone 14 as the precursor for 4-chloro-o-quinodimethane 13.
The synthesis of ethyl 1-(6-chloro-3-(methylsulfonyl)-naphthalen-2-yl)-3-methyl-1H-pyrazole-5-carboxylate 7 and its corresponding 2-(7-chloro-3-methylsulfonyl)-naphthyl isomer 7B is illustrated in Chart 2. Diol 18 was readily prepared from commercially available 4-chlorophthalic anhydride 16 using lithium aluminum hydride (LAH) (Ͼ80% yield) and also from commercially available 4-chlorophthalic acid 17 using borane-tetrahydrofuran (THF) (Ͼ70% yield). a,aЈ-Dibromo-o-xylene 19 was produced from diol 18 in refluxed 48% HBr quantitatively. Under Dittmer's condition, 12, 13) compound 19 reacted smoothly with sodium hydroxymethanesulfinate to afford a mixture of 1,4-dihydro-2,3-benzoxathiin-3-oxides 15A/B in 1 : 1 ratio in 60% yield. In refluxed benzene, mixture 15A/B decomposed to 4-chloro-o-quinodimethane 13, which then underwent DielsAlder reaction with maleic anhydride to cleanly generate 6-chloro-1,2,3,4-tetrahydro-2,3-naphthalic anhydride 12. Its aromatization to 6-chloro-2,3-naphthalic anhydride 11 was accomplished using NBS (N-bromosuccinimide) in boiling acetic anhydride. 11) Naphthalic anhydride 11 was converted to its half esters 10A/B (inseparable) with sodium methoxide and next to the corresponding tert-butoxycarbonyl (BOC)-protected naphthylamine derivatives 20A/B (inseparable) via Curtius rearrangement using diphenylphosporyl azide (DPPA). 11, 12) Compounds 20A/B were purified by flash column and their overall yield from 15A/B was 60%. The BOC protecting group was then cleaved by HCl, and the resulted naphthylamines 9A/B (1 : 1 by HPLC, yet separable by challenging flash column work) were converted to iodonaphthalenes 21A/B (inseparable) through iodo-de-diazoniation. 18) Methyl esters 21A/B were hydrolyzed into naphthyl carboxylic acids 22A/B, which were converted to the corresponding BOCprotected naphthylamines 23A/B via another Curtius rearrangement. Compounds 23A/B (inseparable) were purified by flash column, and their overall yield from 20A/B was 37%. Treatment of 23A/B with 4 N HCl in dioxane offered the HCl salt of 6-chloro-3-iodonaphthyl-2-amine 8A and 7-chloro-3-iodonaphthyl-2-amine 8B.
Naphthylamines 8A/B were converted to hydrazines 24A/B using the same procedure we had reported earlier.
7) It was then condensed with mono-protected diketone 25 to afford naphthyl pyrazoles 26A/B (1 : 1 by HPLC; overall 12% yield from 23A/B). 6-Chloro-3-iodo-2-naphthyl pyrazole Chart 1. Retrosynthesis of Key Pyrazole Intermediate 7 (a) LAH (1 M at THF, 2.5 eq), THF, room temperature (RT), 2 h, Ͼ80%; (b) BH 3 · THF (1 M in THF, 10 eq), dioxane, 0°C to RT, 1 h, Ͼ70%; (c) 48% HBr, reflux, 4 h, 95%; (d) sodium hydroxymethanesulfinate dihydrate (2 eq), Bu 4 NBr (0.2 eq), DMF, 0°C to RT, overnight, 60%; (e) maleic anhydride (1 eq), PhH, reflux, overnight; (f) NBS (2 eq), AIBN (cat.), Ac 2 O, 120°C, 4 h; (g) (1) NaOMe (50 eq), MeOH, reflux, 3 h; (2) conc. HCl; (h) DPPA (1.1 eq), Et 3 N (1.1 eq), tBuOH, reflux, overnight; flash column purification with 10% EtOAc in hexane; (i) HCl (4 N in dioxane), 2 h; (j) (1) NaNO 2 (1 eq), conc. HCl, 0°C, 40 min; (2) NaI (4 eq in water), overnight, 0°C to RT; (k) (1) LiOH · H 2 O (2 eq), MeOH, THF, water, RT, 90 min; (2) conc. HCl; (l) (1) NaNO 2 (1 eq), conc. HCl, 0°C, 30 min; (2) SnCl 2 · 2H 2 O (3 eq), conc. HCl, 0°C, 30 min; cold filtration to isolate solid product; (m) 25 (1 eq), THF/HOAc (2 : 1), reflux, 3 h; silica flash column purification with 5% EtOAc in hexane to separate 26A and 26B; (n) MeSO 2 Na (4 eq), (CuOTf) 2 · PhH (0.5 eq), MeNHCH 2 CH 2 NHMe (0.5 eq), DMSO, 115°C, 3 h; flash column purification with 10-20% EtOAc in hexane; 50%.
Chart 2
26A and its 7-chloro-3-iodo-2-naphthyl regioisomer 26B were separated from each other by silica flash column using 5% EtOAc in hexane. Compound 26B has a slightly higher Rf value than its regioisomer 26A. Ethyl 1-(6-chloro-3-(methylsulfonyl)naphthalen-2-yl)-3-methyl-1H-pyrazole-5-carboxylate 7 was then successfully prepared from compound 26A in about 50% yield by the Cu(I)-promoted C-S cross coupling reaction. 10, 19) So was ethyl 1-(7-chloro-3-(methylsulfonyl)naphthalen-2-yl)-3-methyl-1H-pyrazole-5-carboxylate 7B prepared from compound 26B. The structures of 7 and 7B were determined by proton NMR NOE study. 20) Finally, the synthesis of 6-chloro-3-methylsulfonyl fXa inhibitors 5 and 6, along with their corresponding 7-chloro-3-methylsulfonyl regioisomers 29 and 30, was completed by the route shown in Chart 3. 21, 22) Weinreb reactions 23) were used to couple the biphenylamines (27, 28) 24) with ethyl esters 7 and 7B in 40-60% yield. The amino-protecting tbutyl groups were cleaved using warm trifluoroacetic acid (TFA) to liberate the sulfonamide functionality in compounds 5 and 29.
The biological activity data for the biphenyl 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides are summarized in Table 1 . It is clear that the 7-chloro (Z 7 ) substituent in compounds 29 and 30 is not tolerated in the fXa S1 pocket, due to its unfavorable geometrical orientation. We were delighted to learn that the 6-chloro-3-methylsulfonyl compounds 5 (fXa IC 50 0.5 nM; K i 0.065 nM) and 6 (fXa IC 50 0.6 nM; K i 0.045 nM) are highly potent fXa inhibitors. 25, 26) Their fXa binding affinity is about 10-fold better than that of the corresponding 6-chloro analogs (1, 2), and is also about 10-fold better than that of the corresponding 3-methylsulfonyl analogs (3, 4) . This observation confirms that the Z 3 (3-methylsulfonyl) and Z 6 (chloro) substituents are synergetic to each other for the 2-naphthyl's binding interaction in the fXa S1 pocket. Like inhibitors 1-4, compounds 5 and 6 have displayed excellent enzyme selectivity toward fXa. Their IC 50 values for thrombin, trypsin, tissue plasminogen activator, activated protein C and plasmin are all above 10 mM.
The kallikrein IC 50 values for compounds 5 and 6 are 1.6 mM and 1.9 mM, respectively. Unfortunately, fXa inhibitors 5 (2ϫmaximum thrombin generation (TG) 2.5 mM) and 6 (2ϫTG 4.6 mM) have not displayed strong in vitro anticoagulant activity in our human plasma thrombin generation assay, 27) probably due to their poor hydrophilicity and the resulted high plasma protein binding. However, as we have reported previously, the fXa inhibitors' hydrophilicity and in vitro anticoagulant potency can be significantly improved by changing and optimizing the P4 moieties, without compromising the potent fXa binding affinity. 8, 9) Hopefully, the optimal P4 motifs we have discovered can lead us to potent 1-(2-(6-chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamide-based fXa inhibitors with improved anticoagulant activity and desired pharmacokinetic properties.
In conclusion, we have designed and synthesized biphenyl 1-(2-(6-chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides 5 and 6 as highly potent fXa inhibitors. We have discovered that the 2-(6-chloro-3-methylsulfonyl)-naphthyl is a more potent fXa S1 binding element than the 2-(6-chloro)-naphthyl and the 2-(3-methylsulfonyl)-naphthyl in the class of 1-(2-naphthyl)-1H-pyrazole-5-carboxylamidebased fXa inhibitors, due to the synergetic effect of the 6-chloro and the 3-methylsulfonyl groups to the S1 binding interaction. 
